VRCA vs PRGO vs MCK vs CAH vs HSIC

For growth investors, Verrica Pharmaceuticals Inc.

(VRCA) is the stronger pick with 370. 2% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 6x trailing P/E (13. 3x forward), making it the more compelling value choice. Analysts rate Verrica Pharmaceuticals Inc. (VRCA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 6x versus McKesson Corporation at 29. 2x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 49x versus Henry Schein, Inc. 's 4. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -92. 8% for Verrica Pharmaceuticals Inc. (VRCA). Over 10 years, the gap is even starker: MCK returned +348. 1% versus VRCA's -95. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cardinal Health, Inc.

(CAH) is the lower-risk stock at 0. 03β versus Verrica Pharmaceuticals Inc. 's 2. 19β — meaning VRCA is approximately 6355% more volatile than CAH relative to the S&P 500. On balance sheet safety, Verrica Pharmaceuticals Inc. (VRCA) carries a lower debt/equity ratio of 7% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Verrica Pharmaceuticals Inc.

(VRCA) is pulling ahead at 370. 2% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Verrica Pharmaceuticals Inc. grew EPS 88. 6% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, VRCA leads at 57. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus -50. 3% for Verrica Pharmaceuticals Inc. — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -33. 6% for VRCA. At the gross margin level — before operating expenses — VRCA leads at 93. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 49x versus Henry Schein, Inc. 's 4. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Perrigo Company plc (PRGO) trades at 5. 6x forward P/E versus 19. 3x for McKesson Corporation — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRCA: 106. 3% to $17. 00.

In this comparison, PRGO (9.

8% yield), CAH (1. 1% yield), MCK (0. 4% yield) pay a dividend. VRCA, HSIC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Verrica Pharmaceuticals Inc. (VRCA) carries a higher beta of 2. 19 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CAH: +160. 8%, VRCA: -95. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VRCA is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock; HSIC is a small-cap quality compounder stock. PRGO, CAH pay a dividend while VRCA, MCK, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.